WILMINGTON, DE — The U.S. Food and Drug Administration recently approved RAPIBLYK® (landiolol) for pediatric patients from birth to under 18 years old with supraventricular tachycardia, expanding its use beyond adults to all age groups in hospital settings.
The approval provides a treatment option for pediatric patients with SVT, a condition involving abnormally fast heart rhythms that often require rapid management in acute care environments.
The decision was supported by data from the LANDI-PED study, which included 60 pediatric patients and showed more than a 20% reduction in ventricular rate from baseline in appropriate patients.
“With this expanded indication, RAPIBLYK® becomes available as a treatment option for pediatric patients with SVT in the U.S.,” said John Kimmet, general manager of AOP Health US.
Rapiblyk is an intravenous beta-1 adrenergic receptor blocker designed for short-term control of heart rate, with rapid onset and offset of action in monitored hospital settings.
The drug was previously approved for adults with SVT, including atrial fibrillation and atrial flutter, particularly in perioperative and critical care situations.
AOP Health US, established in 2025, is part of the Austria-based AOP Health Group, which focuses on therapies for cardiovascular and rare diseases.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.